Production of dentin, cementum and enamel by cells

Patent metadata

Field	Value
Publication number	US-9597359-B2
Application number	US-201113877262-A
Country	US
Kind code	B2
Filing date	Oct 3, 2011
Priority date	Oct 1, 2010
Publication date	Mar 21, 2017
Grant date	Mar 21, 2017

Abstract

Described is a method of forming a mineralized material by co-culturing epithelial cell, such as ameloblast, and mesenchymal cell, such as osteoblast or odontoblast, in a mineral-stimulating medium. Also described is a matrix seeded with epithelial cells and mesenchymal cells and infused with a mineral-stimulating medium capable of forming a mineralized material in the matrix. Methods of manufacturing such compositions and methods of treating mineralization-related conditions are also described.

First claim

What is claimed is:

1. A method of forming a mineralized composition comprising:
forming a mineralization composition comprising combining
(i) ameloblasts;
(ii) osteoblasts or odontoblasts; and
(iii) an osteogenic medium comprising ascorbic acid and glycerophosphate; and
adding amelogenin into the osteogenic medium in an amount sufficient to increase nuclear translocalization of β-catenin, increase activation of β-catenin, or increase accumulation of non-phosphorylated β-catenin;
culturing the mineralization composition under conditions suitable to induce production of a mineralized material; and
forming a mineralized composition comprising enamel, dentin, or cementum.

2. The method of claim 1 , wherein the amelogenin comprises naturally occurring or recombinant amelogenin.

3. The method of claim 1 , wherein forming the mineralized composition further comprises:
introducing the mineralization composition into a matrix material.

4. The method of claim 3 , wherein the matrix material comprises a material selected from the group consisting of fibrin, fibrinogen, a collagen, a polyorthoester, a polyvinyl alcohol, a polyamide, a polycarbonate, a polyvinyl pyrrolidone, a marine adhesive protein, a cyanoacrylate, and a polymeric hydrogel, or a combination thereof.

5. The method of claim 3 , wherein the matrix material comprises at least one physical channel.

6. The method of claim 3 , wherein the (i) ameloblasts and (ii) osteoblasts or odontoblasts are independently present in the matrix material at a density of from about 0.0001 million cells per ml up to about 1000 million cells per ml.

7. The method of claim 3 , wherein a ratio of the (i) ameloblasts to (ii) osteoblasts or odontoblasts in the matrix material is about 100:1 to about 1:100.

8. The method of claim 3 , further comprising:
introducing progenitor cells into the matrix material;
differentiating at least a first portion of the progenitor cells to form the ameloblasts; and
differentiating at least a second portion of the progenitor cells to form the osteoblasts or odontoblasts.

9. The method of claim 1 , further comprising:
differentiating a first plurality of progenitor cells to form the ameloblasts;
differentiating a second plurality of progenitor cells to form the osteoblasts or odontoblasts; or
differentiating progenitor cells to form the epithelial cells and mesenchymal cells.

10. The method of claim 9 , wherein the progenitor cells comprise embryonic stem cells, umbilical cord stem cells, adult stem cells, dental stem cells, or induced pluripotent stem cells.

11. The method of claim 1 , wherein culturing the mineralization composition comprises in vitro culturing.

12. The method of claim 1 , wherein culturing the mineralization composition comprises in vitro culturing and mineralized material forms in a cell culture or matrix material.

13. The method of claim 1 , wherein culturing the mineralization composition comprises in vivo culturing and mineralized material forms in a tissue or organ of a subject.

14. The method of claim 1 , wherein said culturing the mineralization composition comprises in vivo culturing.

15. The method of claim 1 , wherein:
the ascorbic acid is present at a concentration of 50 μg/ml of the osteogenic medium; and
the glycerophosphate is present at a concentration of 10 mM of the osteogenic medium.

16. The method of claim 1 , wherein the osteogenic medium further comprises dexamethasone.

17. The method of claim 16 , wherein the dexamethasone is present at a concentration of 1 mM of the osteogenic medium.

18. The method of claim 1 , wherein the concentration of the amelogenin is 1 μg/ml, 3 μg/ml, or 5 μg/ml.

19. An engineered tissue composition comprising:
(a) ameloblasts;
(b) osteoblasts or odontoblasts;
(c) an osteogenic medium comprising ascorbic acid, glycerophosphate, dexamethasone, and
(d) adding amelogenin into the osteogenic medium in an amount sufficient to increase nuclear translocalization of β-catenin, increase activation of β-catenin, or increase accumulation of non-phosphorylated β-catenin; and
(e) a matrix material;
wherein,
the ameloblasts and the osteoblasts or odontoblasts are present in the matrix material;
the osteogenic medium is infused in the matrix material; and
the ameloblasts and the osteoblasts or odontoblasts are fluidly connected through the osteogenic medium.

20. The composition of claim 19 , wherein at least one of the following is satisfied:
(i) the ameloblasts are differentiated from progenitor cells selected from the group consisting of embryonic stem cells, umbilical cord stem cells, adult stem cells, dental stem cells, and induced pluripotent stem cells;
(ii) the osteoblasts or odontoblasts are differentiated from progenitor cells selected from the group consisting of embryonic stem cells, umbilical cord stem cells, adult stem cells, dental stem cells, and induced pluripotent stem cells;
(iii) osteogenic medium comprises naturally occurring or recombinant amelogenin;
(iv) the matrix material comprises a material selected from the group consisting of fibrin, fibrinogen, a collagen, a polyorthoester, a polyvinyl alcohol, a polyamide, a polycarbonate, a polyvinyl pyrrolidone, a marine adhesive protein, a cyanoacrylate, and
a polymeric hydrogel, or a combination thereof;
(v) the matrix material comprises at least one physical channel;
(vi) the ameloblasts and the osteoblasts or odontoblasts are independently present in the matrix material at a density of from about 0.0001 million cells per ml up to about 1000 million cells per ml;
(vii) a ratio of the ameloblasts to the osteoblasts or odontoblasts in the matrix material is about 100:1 to about 1:100; or
(viii) the engineered tissue composition is suitable for in vitro culturing or in vivo culturing, or both.

21. The composition of claim 19 , wherein:
the ascorbic acid is present at a concentration of 50 μg/ml of the osteogenic medium;
the glycerophosphate is present at a concentration of 10 mM of the osteogenic medium; and
the dexamethasone is present at a concentration of 1 mM of the osteogenic medium.

22. A method of treating a mineralization-related tissue or organ defect comprising grafting a composition according to claim 19 into a subject in need thereof.

23. A method of forming a mineralized composition comprising:
differentiating a first plurality of progenitor cells to form ameloblasts;
differentiating a second plurality of progenitor cells to form osteoblasts or odontoblasts;
forming a mineralization composition comprising combining
(i) the ameloblasts;
(ii) the osteoblasts or odontoblasts; and
(iii) an osteogenic medium comprising ascorbic acid and glycerophosphate;
adding amelogenin in an amount sufficient to increase nuclear translocalization of β-catenin, increase activation of β-catenin, or increase accumulation of non-phosphorylated β-catenin;
culturing the mineralization composition under conditions suitable to induce production of a mineralized material; and
forming a mineralized composition comprising enamel, dentin, or cementum.

24. A method of forming a mineralized composition comprising:
forming a first mineralization composition comprising ameloblasts in a first osteogenic medium comprising ascorbic acid and glycerophosphate;
forming a second mineralization composition comprising osteoblasts or odontoblasts in a second osteogenic medium comprising ascorbic acid and glyceropho

Assignees

• Mao Jeremy J
• Chen Mo
• Univ Columbia

Inventors

• Mao Jeremy J
• Chen Mo

Classifications

• C12N2500/38

  Vitamins · CPC title

• A61K35/36

  Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells (islets of Langerhans A61K35/39) · CPC title

• A23L33/10

  using additives (addition of substantially indigestible substances A23L33/21) · CPC title

• C12N2501/39

  Steroid hormones · CPC title

• A23V2200/312

  having an effect on dental health · CPC title